Background It has been shown that amyloid ？ (Aβ), a product of proteolytic cleavage of the amyloid β precursor protein (APP), accumulates in neuronal cytoplasm in non-affected individuals in a cell type–specific amount. Methodology/Principal Findings In the present study, we found that the percentage of amyloid-positive neurons increases in subjects diagnosed with idiopathic autism and subjects diagnosed with duplication 15q11.2-q13 (dup15) and autism spectrum disorder (ASD). In spite of interindividual differences within each examined group, levels of intraneuronal Aβ load were significantly greater in the dup(15) autism group than in either the control or the idiopathic autism group in 11 of 12 examined regions (p<0.0001 for all comparisons; Kruskall-Wallis test). In eight regions, intraneuronal Aβ load differed significantly between idiopathic autism and control groups (p<0.0001). The intraneuronal Aβ was mainly N-terminally truncated. Increased intraneuronal accumulation of Aβ17–40/42 in children and adults suggests a life-long enhancement of APP processing with α-secretase in autistic subjects. Aβ accumulation in neuronal endosomes, autophagic vacuoles, Lamp1-positive lysosomes and lipofuscin, as revealed by confocal microscopy, indicates that products of enhanced α-secretase processing accumulate in organelles involved in proteolysis and storage of metabolic remnants. Diffuse plaques containing Aβ1–40/42 detected in three subjects with ASD, 39 to 52 years of age, suggest that there is an age-associated risk of alterations of APP processing with an intraneuronal accumulation of a short form of Aβ and an extracellular deposition of full-length Aβ in nonfibrillar plaques. Conclusions/Significance The higher prevalence of excessive Aβ accumulation in neurons in individuals with early onset of intractable seizures, and with a high risk of sudden unexpected death in epilepsy in autistic subjects with dup(15) compared to subjects with idiopathic ASD, supports the concept of mechanistic and functional links between autism, epilepsy and alterations of APP processing leading to neuronal and astrocytic Aβ accumulation and diffuse plaque formation.
References
[1]
American Psychiatric , Statistical Manual of Mental Disorders DSM-IV-TR (2000) Washington, DC: American Psychiatric Association. 943 p.
[2]
Rineer S, Finucane B, Simon EW (1998) Autistic symptoms among children and young adults with isodicentric chromosome 15. Am J Med Genet 81: 428–433.
[3]
Simon EW, Finucane B, Rineer S (2000) Autistic symptoms in isodicentric 15 syndrome: response to Wolpert, et al. Am J Med Genet (Neuropsychiat Genet) 96: 432–433.
[4]
Hagerman RJ (2002) The physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research. 3rd ed. Baltimore: John Hopkins University Press. pp. 3–109.
[5]
Kent L, Evans J, Paul M, Sharp M (1999) Comorbidity of autistic spectrum disorders in children with Down syndrome. Dev Med Child Neurol 41: 153–158.
[6]
Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, et al. (2006) High levels of Alzheimer beta- amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol 21: 444–449.
[7]
Westmark CJ, Malter JS (2007) FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS One Biology 5: e52.
[8]
Westmark CJ, Westmark PR, O’Riordan KJ, Ray BC, Hervey CM, et al. (2011) Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice. PloS One 6(10): e26549.
[9]
Bailey AR, Giunta BN, Obregon D, Nikolic WV, Tiaqn J, et al. (2008) Peripheral biomarkers in autism: secreted amyloid precursor protein-α as a probable key player in early diagnosis. Int J Clin Exp Med 1: 338–344.
[10]
Sokol DK, Maloney B, Long JM, Ray B, Lahiri DK (2011) Autism, Alzheimer disease, and fragile X. APP, FMRP, and mGluR5 are molecular links. Neurology 76: 1344–1352.
[11]
Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS (1995) The toxicity in vitro of beta-amyloid protein. (Review). Biochem J 311: 1–16.
[12]
Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 181: 741–766.
[13]
Sevalle J, Amoyel A, Robert P (2009) Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Neurochem 109: 248–256.
[14]
Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E (2010) Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol 119: 523–541.
[15]
Bayer TA, Wirths O (2010) Intracellular accumulation of amyloid-beta–a predictor of synaptic dysfunction and neuron loss in Alzheimer’s disease. Front Aging Neurosci 2: 1–10.
[16]
Ray B, Long JM, Sokol DK, Lahiri DK (2011) Increased secreted amyloid precursor protein-α (sAPPα) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. PloS One 6: e20405, 1–10:
[17]
Westmark CJ, Westmark PR, Malter JS (2010) MPEP reduces seizure severity in Fmr-1 KO mice overexpressing human Aβ. Int J Clin Exp Pathol 3: 56–68.
[18]
Tuchman RF, Rapin I (2002) Epilepsy in autism. Lancet Neurol 1: 352–358.
[19]
Moechars D, Lorent K, De Strooper B, Dewachter I, Van Leuven F (1996) Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J 15: 1265–1274.
[20]
Westmark CJ, Westmark PR, Beard AM, Hildebrandt SM, Malter JS (2008) Seizure susceptibility and mortality in mice that over-express amyloid precursor protein. Int J Clin Exp Pathol 1: 157–168.
[21]
Wegiel J, Kuchna I, Nowicki K, Frackowiak J, Mazur Kolecka B, et al. (2007) Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropath 113: 389–402.
[22]
Mochizuki A, Tamaoka A, Shimohata A, Komatsuzaki Y, Shoji S (2000) Aβ42-positive non-pyramidal neurons around amyloid plaques in Alzheimer’s disease. Lancet 355: 42–43.
[23]
Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC (2001) Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125: 489–492.
[24]
D’Andrea MR, Nagele RG, Wang H-Y, Peterson PA, Lee DHS (2001) Evidence that neurons accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer’s disease. Histopathology 38: 120–134.
[25]
Winton MJ, Lee EB, Sun E, Wong MM, Leight S, et al. (2011) Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration. J Neurosci 31: 7691–7699.
[26]
Frackowiak J, Miller DL, Potempska A, Sukontasup T, Mazur-Kolecka B (2003) Secretion and accumulation of Aβ by brain vascular smooth muscle cells from A βPP-Swedish transgenic mice. J Neuropathol Exp Neurol 62: 685–696.
[27]
Frackowiak J, Sukontasup T, Potempska A, Mazur-Kolecka B (2004) Lysosomal deposition of Aβ in cultures of brain vascular smooth muscle cells is enhanced by iron. Brain Res 1002: 67–75.
[28]
Wegiel J, Schanen NC, Cook EH, Sigman M, Brown WT, et al. (2012) Difference between the patterns of developmental abnormalities in autism associated with duplications 15q11.2q13 and idiopathic autism. J Neuropath Exp Neurol. In press.
[29]
Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, et al. (1997) Alzheimer’s Aβ (1–42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 3: 1021–1023.
[30]
Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, et al. (1997) Distinct sites of intracellular production for Alzheimer’s disease Aβ40/42 amyloid peptides. Nat Med 3: 1016–1020.
[31]
Greenfield JP, Tsai J, Gouras GK, Hai B, Thinakaran G, et al. (1999) Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β-amyloid peptides. Proc Natl Acad Sci U S A 96: 742–747.
[32]
Glabe C (2001) Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer’s disease. J Mol Neurosc 17: 137–145.
[33]
Wilson CA, Doms RW, Lee VM-Y (1999) Intracellular APP processing and Aβ production in Alzheimer disease. J Neuropathol Exp Neurol 58: 787–794.
[34]
Takahashi RH, Milner TA, Li F, Nam EN, Edgar MA, et al. (2002) Intraneuronal Alzheimer Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161: 1869–1879.
[35]
Caspersen C, Wang N, Yao J, Sosunov A, Chen X, et al. (2005) Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J 19: 2040–2041.
[36]
Sheikh AM, Li X, Wen G, Tauqeer Z, Brown WT, et al. (2010) Cathepsin D and apoptosis related proteins elevated in the brain of autistic subjects. Neuroscience 165: 363–370.
[37]
Gordon PB, Hoyvik H, Seglen PO (1992) Prelysosomal and lysosomal connections between autophagy and endocytosis. Biochem J 283: 361–369.
[38]
Noda T, Farquhar MG (1992) A non-autophagic pathway for diversion of ER secretory proteins to lysosomes. J Cell Biol 119: 85–97.
[39]
Brunk UT, Terman A (2002) Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med 33: 611–619.
[40]
Brody H (1960) The deposition of aging pigment in the human cerebral cortex. J Geront 15: 258–261.
[41]
Bancher C, Grundke-Iqbal I, Kim KS, Wisniewski HM (1989) Immunoreactivity of neuronal lipofuscin, with monoclonal antibodies to the amyloid β-protein. Neurobiol Aging 10: 125–132.
[42]
Lopez-Hurtado E, Prieto JJ (2008) A microscopic study of language-related cortex in autism. Am J Biochem Biotechn 4: 130–145.
[43]
Jellinger K, Armstrong D, Zoghbi HY, Percy AK (1988) Neuropathology of Rett syndrome. Acta Neuropathol 76: 142–158.
[44]
Yanik M, Vural H, Tutkun H, Zoroglu SS, Savas HA, et al. (2004) The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 254: 43–47.
[45]
Herken H, Uz E, Ozyurt H, Sogut S, Virit O, et al. (2001) Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6: 66–73.
[46]
Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, et al. (2002) The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 26: 995–1005.
[47]
Sohal RS, Brunk UT (1989) Lipofuscin as an indicator of oxidative stress and aging. Adv Exp Med Biol 266: 17–26.
[48]
Brunk U T, Jones CB, Sohal RS (1992) A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. Mutat Res 275: 395–403.
[49]
Brunk UT, Terman A (2002) The mitochondrial-lysosomal axis theory of aging: accumulation of damaged mitochondria as a result of imperfect autophagocytosis. Eur J Biochem 269: 1996–2002.
[50]
Terman A, Brunk UT (2004) Lipofuscin. Int J Biochem Cell Biol 36: 1400–1404.
[51]
Chauhan A, Chauhan V, Brown WT, Cohen I (2004) Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin–the antioxidant proteins. Life Sci 75: 2539–2549.
[52]
Chauhan V, Chauhan A (2010) Abnormalities in membrane lipids, membrane-associated proteins, and signal transduction in autism. In: Chauhan A, Chauhan V, Brown WT, editors. Autism. Oxidative stress, inflammation and immune abnormalities. Boca RatonFL: CRC Press, Taylor and Francis Group. pp. 177–206.
Pigino G, Morfini G, Atagi Y, Deshpande A, Yu C, et al. (2009) Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. PNAS 106: 5907–5912.
Wei W, Norton DD, Wang X, Kusiak JW (2002) Aβ 17–42 in Alzheimer’s disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 125: 2036–2043.
[57]
Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, et al. (1994) Chemical characterization of Aβ17–42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 269: 10987–10990.
[58]
Saido TC, Iwatsubo T, Mann DMA, Shimada H, Ihara Y, et al. (1995) Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 14: 457–466.
[59]
Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, et al. (2000) Intraneuronal Aβ42 accumulation in human brain. Am J Pathol 156: 15–20.
[60]
Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Wisniewski HM, et al. (1996) The “nonamyloidogenic “ p3 fragment (amyloid β 17–24) is a major constituent of Down’s syndrome cerebellar preamyloid. J Biol Chem 271: 33623–33631.
[61]
Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, Masters CL (1989) A4 protein in Alzheimer’s disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol 48: 674–691.
[62]
Mann DMA, Brown AMT, Prinja D, Davies CA, Landon M, et al. (1989) An analysis of the morphology of senile plaques in Down’s syndrome patients of different ages using immunocytochemical and lectin histochemical techniques. Neuropathol Appl Neurobiol 15: 317–329.
[63]
Tagliavini F, Giaccone G, Linoli G, Frangione B, Bugiani O (1989) Cerebral extracellular preamyloid deposits in Alzheimer’s disease, Down syndrome and nondemented elderly individuals. Prog Clin Biol Res 317: 1001–1005.
[64]
Dickson DW (1997) The pathogenesis of senile plaques. J Neuropath Exp Neurol 56: 321–339.
[65]
Probst A, Langui D, Ipsen S, Robakis N, Ulrich J (1991) Deposition of beta/A4 protein along neuronal plasma membranes in diffuse senile plaques. Acta Neuropathol 83: 21–29.
[66]
Wisniewski HM, Wegiel J, Kotula L (1996) Some neuropathological aspects of Alzheimer disease and its relevance to other disciplines. Neuropath Appl Neurob 22: 3–11.
[67]
Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J (1998) Diffuse, lake-like amyloid- ？ deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropat Exp Neurol 57: 674–683.
[68]
Wegiel J, Wisniewski H (1999) Projections of neurons in neuritic plaques formation. NeuroScience News 2: 34–39.
[69]
Thal DR, H？rtig W, Schober R (1999) Diffuse plaques in the molecular layer show intracellular Aβ8–17 immunoreactive deposits in subpial astrocytes. Clin Neuropath 18: 226–231.
[70]
Funato H, Yoshimura M, Yamazaki T, Saido TC, Ito Y, et al. (1998) Astrocytes containing amyloid β-protein (Aβ)-positive granules are associated with Aβ40-positive diffuse plaques in the aged human brain. Am J Pathol 152: 983–992.
[71]
Yamaguchi H, Sugihara S, Ogawa A, Saido TC, Ihara Y (1998) Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques. Acta Neuropathol 95: 271–222.
[72]
DeKosky ST, Abrahamson EE, Ciallella JR (2007) Association of increased cortical soluble Aβ42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol 64: 541–544.
[73]
Gentleman SM, Greenberg BD, Savage MJ, Noori M, Newman SJ, et al. (1997) A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury. Neuroreport 8: 1519–1522.
[74]
McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte T, Gavett BE, et al. (2009) Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 68: 709–735.
[75]
Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, et al. (1994) Beta amyloid protein deposition in the brain after severe head injury: Implications for the pathogenesis of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 57: 419–425.
[76]
Murakami N, Yamaki T, Iwamoto Y, Sakakibara T, Kobori N, et al. (1998) Experimental brain injury induces expression of amyloid precursor protein, which may be related to neuronal loss in the hippocampus. J Neurotrauma 15: 993–1003.
[77]
Ikonomovic MD, Uryu K, Abrahamson EE (2004) Alzheimer’s pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 190: 192–203.
[78]
Ohm TG, Müller H, Braak H, Bohl J (1995) Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer’s disease-related neurofibrillary changes. Neuroscience 64: 209–217.
[79]
Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24: 659–685.
[80]
Mann SM, Wang NJ, Liu DH, Wang L, Schultz RA (2004) Supernumerary tricentric derivative chromosome 15 in two boys with intractable epilepsy: another mechanism for partial hexasomy. Hum Genet 115: 104–111.
[81]
Wang NJ, Liu D, Parokonny AS, Schanen NC (2004) High-resolution molecular characterization of 15q11-q13 rearrangements by array comparative genomic hybridization (array CGH) with detection of gene dosage. Am J Hum Genet 75: 267–281.
[82]
Wegiel J, Kuchna I, Nowicki K, Imaki H, Wegiel J, et al. (2010) The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropath 119: 755–770.
[83]
Iqbal K, Braak H, Braak E, Grundke-Iqbal I (1993) Silver labeling of Alzheimer neurofibrillary changes and brain β-amyloid. J Histotech 16: 335–342.
[84]
Kim KS, Wen GY, Bancher C, Chen CMJ, Sapienza VJ, et al. (1990) Detection and quantitation of amyloid β-peptide with 2 monoclonal antibodies. Neurosci Res Comm 7: 113–122.
[85]
Miller DL, Currie JR, Mehta PD, Potempska A, Hwang Y-W, et al. (2003) Humoral immune response to fibrillar β-amyloid peptide. Biochemistry 42: 11682–11692.
[86]
Kim KS, Miller DL, Sapienza VJ, Chen CMJ, Bai C, et al. (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun 2: 121–130.
[87]
Miller DL, Potempska A, Wegiel J, Mehta PD (2011) High-affinity rabbit monoclonal antibodies specific for amyloid peptides amyloid-β40 and amyloid-β42 J Alz Dis 23: 293–305.
[88]
Kitamoto T, Ogomori K, Tateishi J, Prusiner S (1987) Methods in laboratory investigation. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 57: 230–236.
[89]
Goedert M, Spillantini M, Jakes R, Rutherford D, Crowther R (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3: 519–526.
[90]
Siegal S, Castellan NJ (1988) Nonparametric statistics for the behavioral sciences, 2nd ed. New York: McGraw Hill Book Company. pp. 206–212.
